Orion Portfolio Solutions LLC Increases Stock Holdings in argenx SE (NASDAQ:ARGX)

Orion Portfolio Solutions LLC increased its holdings in shares of argenx SE (NASDAQ:ARGX) by 2.5% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 9,335 shares of the company’s stock after purchasing an additional 228 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in argenx were worth $3,675,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Capital World Investors increased its stake in shares of argenx by 37.0% during the 4th quarter. Capital World Investors now owns 1,961,202 shares of the company’s stock valued at $746,099,000 after acquiring an additional 530,181 shares during the last quarter. Artisan Partners Limited Partnership grew its holdings in argenx by 12.2% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,174,477 shares of the company’s stock valued at $1,207,666,000 after purchasing an additional 346,178 shares during the period. Avoro Capital Advisors LLC increased its position in argenx by 23.5% during the fourth quarter. Avoro Capital Advisors LLC now owns 1,234,567 shares of the company’s stock worth $469,666,000 after purchasing an additional 234,567 shares during the last quarter. RTW Investments LP raised its stake in argenx by 31.5% during the fourth quarter. RTW Investments LP now owns 667,195 shares of the company’s stock worth $253,821,000 after purchasing an additional 160,000 shares during the period. Finally, Braidwell LP acquired a new position in shares of argenx in the 4th quarter valued at $58,283,000. 60.32% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ARGX has been the topic of a number of research analyst reports. Truist Financial lifted their target price on argenx from $440.00 to $480.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Piper Sandler boosted their target price on argenx from $522.00 to $535.00 and gave the stock an “overweight” rating in a report on Monday, June 24th. Stifel Nicolaus increased their target price on shares of argenx from $485.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. JPMorgan Chase & Co. reduced their price target on shares of argenx from $560.00 to $500.00 and set an “overweight” rating on the stock in a research report on Monday, May 13th. Finally, Scotiabank increased their price objective on shares of argenx from $402.00 to $408.00 and gave the stock a “sector perform” rating in a research report on Tuesday, March 26th. Five analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $533.47.

argenx Stock Up 1.0 %

Shares of ARGX traded up $4.76 during trading on Friday, reaching $471.32. The company’s stock had a trading volume of 396,592 shares, compared to its average volume of 315,430. The company has a market cap of $28.01 billion, a price-to-earnings ratio of -83.27 and a beta of 0.64. The company has a fifty day moving average of $404.75 and a two-hundred day moving average of $392.02. argenx SE has a twelve month low of $327.73 and a twelve month high of $550.76.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Monday, May 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.33). The company had revenue of $412.51 million during the quarter, compared to analyst estimates of $404.03 million. argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. During the same period in the prior year, the company earned ($0.52) earnings per share. As a group, equities analysts forecast that argenx SE will post -2.93 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.